Article Details
Retrieved on: 2022-10-10 11:05:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Trilaciclib, an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system ...
Article found on: www.bakersfield.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here